Genmab’s Total Number of Voting Rights and Total Share

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab’s Total Number of Voting Rights and Total Share Capital

Copenhagen, Denmark; May 31, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announces that p ursuant to section 10 of Executive Order no. 1258 of November 9, 2015 on Issuers' Disclosure Obligations, the total nominal value of Genmab A/S' share capital is DKK 59 ,833,932 at the end of May 2016, which is made up of 59 ,833,932 shares of a nominal value of DKK 1 each, corresponding to 59 ,833,932 votes.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .   

Contact:          Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo ® ; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 27 CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 38

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 106

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 122

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 101

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 161

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 142

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 79

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

Highlights and Expectations for AAR's Upcoming Earnings Call

Updated Category News Views 102

AAR's Upcoming Earnings Release AAR (NYSE:AIR) is set to unveil its quarterly earnings report soon. Investors keenly await this announcement, hoping for positive surprises both in earnings and guidance for the future. Analysts’ Earnings Expectations Analysts predict that AAR will post an earnings per share (EPS) of $1.03. This figure reflects the optimism surrounding...

Continue Reading
Tradeweb Markets Reports Significant Trading Volume Growth

Updated Category News Views 218

Tradeweb Markets Sees Record Trading Volume in January Tradeweb Markets Inc. (NASDAQ: TW), a premier global provider of electronic marketplaces for trading various financial instruments, reported a phenomenal total trading volume of $54.6 trillion for January 2025. This figure represents an average daily volume (ADV) of approximately $2.44 trillion, showcasing a robust...

Continue Reading
Cal Water Celebrates EPA Recognition for Water Efficiency Efforts

Updated Category News Views 73

California Water Service, trading under NYSE: CWT, scored a big win back in 2024 when it snagged the U. S. Environmental Protection Agency’s (EPA) WaterSense Excellence in Promoting WaterSense Labeled Products Award for the second consecutive year. This ain't just fluff; it reflects a serious commitment to pushing water-efficient solutions that resonate with their...

Continue Reading
Navigating Market Trends: Key Earnings Week Insights

Updated Category News Views 125

Market Trends Before Earnings As we enter a pivotal earnings week, investors are feeling the pressure as tech stocks have led the way downwards. This anticipated decline comes as many anticipate significant corporate earnings that could either uplift or hamper the current record-setting rally in the markets. Stock Performance and Investor Sentiment On this busy Monday...

Continue Reading
Revolutionizing Insurance Research: The Game-Changer ZORRO Discover

Updated Category News Views 145

Introduction to ZORRO Discover ZestyAI has unveiled a groundbreaking tool aimed at transforming the insurance industry: ZORRO Discover. This innovative generative AI agent is set to revolutionize the way insurers handle regulatory filings and competitive market analysis, potentially reshaping operational strategies across the board. Significance of ZORRO Discover...

Continue Reading